N4 Pharma PLC (N4P) - Cash Flow Conversion Efficiency
Based on the latest financial reports, N4 Pharma PLC (N4P) has a cash flow conversion efficiency ratio of -0.251x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-444.37K ≈ $-54.07 USD) by net assets (GBX1.77 Million ≈ $215.03 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
N4 Pharma PLC - Cash Flow Conversion Efficiency Trend (1991–2024)
This chart illustrates how N4 Pharma PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read N4 Pharma PLC total liabilities for a breakdown of total debt and financial obligations.
N4 Pharma PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of N4 Pharma PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Norman Broadbent Plc
LSE:NBB
|
0.147x |
|
Catenai PLC
LSE:CTAI
|
-0.188x |
|
Coro Energy PLC
LSE:CORO
|
-0.278x |
|
Tiger Royalties and investments Plc
LSE:TIR
|
-0.272x |
|
Bangkok Bank Public Company Limited
F:BKKF
|
0.014x |
|
FANDIFI TECHNOLOGY CORP.
F:TQ4
|
N/A |
|
Fitness Champs Holdings Limited Common Stock
NASDAQ:FCHL
|
3.759x |
|
Novae Group Plc
STU:NVAL
|
0.080x |
Annual Cash Flow Conversion Efficiency for N4 Pharma PLC (1991–2024)
The table below shows the annual cash flow conversion efficiency of N4 Pharma PLC from 1991 to 2024. For the full company profile with market capitalisation and key ratios, see how much is N4 Pharma PLC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX651.40K ≈ $79.26 |
GBX-971.50K ≈ $-118.20 |
-1.491x | -47.23% |
| 2023-12-31 | GBX1.19 Million ≈ $145.23 |
GBX-1.21 Million ≈ $-147.11 |
-1.013x | -155.38% |
| 2022-12-31 | GBX2.09 Million ≈ $254.07 |
GBX-828.26K ≈ $-100.78 |
-0.397x | +52.34% |
| 2021-12-31 | GBX2.13 Million ≈ $259.12 |
GBX-1.77 Million ≈ $-215.63 |
-0.832x | -120.69% |
| 2020-12-31 | GBX3.66 Million ≈ $444.99 |
GBX-1.38 Million ≈ $-167.79 |
-0.377x | +53.81% |
| 2019-12-31 | GBX987.34K ≈ $120.13 |
GBX-806.00K ≈ $-98.07 |
-0.816x | +46.56% |
| 2018-12-31 | GBX879.94K ≈ $107.06 |
GBX-1.34 Million ≈ $-163.56 |
-1.528x | -105.62% |
| 2017-12-31 | GBX1.28 Million ≈ $155.71 |
GBX-950.80K ≈ $-115.68 |
-0.743x | -105.70% |
| 2016-12-31 | GBX1.04 Million ≈ $126.66 |
GBX-376.00K ≈ $-45.75 |
-0.361x | +73.14% |
| 2015-12-31 | GBX641.00K ≈ $77.99 |
GBX-862.00K ≈ $-104.88 |
-1.345x | -312.13% |
| 2014-12-31 | GBX1.04 Million ≈ $126.78 |
GBX-340.00K ≈ $-41.37 |
-0.326x | -1194.68% |
| 2013-12-31 | GBX3.45 Million ≈ $420.01 |
GBX-87.00K ≈ $-10.59 |
-0.025x | +71.96% |
| 2012-12-31 | GBX3.60 Million ≈ $438.62 |
GBX-324.00K ≈ $-39.42 |
-0.090x | -131.49% |
| 2011-12-31 | GBX3.49 Million ≈ $424.63 |
GBX996.00K ≈ $121.18 |
0.285x | +238.91% |
| 2010-12-31 | GBX2.96 Million ≈ $359.78 |
GBX249.00K ≈ $30.30 |
0.084x | -70.70% |
| 2009-12-31 | GBX2.63 Million ≈ $319.63 |
GBX755.00K ≈ $91.86 |
0.287x | +323.05% |
| 2008-12-31 | GBX1.43 Million ≈ $173.75 |
GBX-184.00K ≈ $-22.39 |
-0.129x | -194.06% |
| 2007-12-31 | GBX1.17 Million ≈ $142.11 |
GBX160.00K ≈ $19.47 |
0.137x | +284.62% |
| 2006-12-31 | GBX903.00K ≈ $109.87 |
GBX-67.00K ≈ $-8.15 |
-0.074x | +74.52% |
| 2005-12-31 | GBX388.00K ≈ $47.21 |
GBX-113.00K ≈ $-13.75 |
-0.291x | -273.91% |
| 2004-12-31 | GBX836.00K ≈ $101.72 |
GBX140.00K ≈ $17.03 |
0.167x | +255.45% |
| 2003-12-31 | GBX-789.00K ≈ $-96.00 |
GBX85.00K ≈ $10.34 |
-0.108x | -113.63% |
| 2002-12-31 | GBX-935.00K ≈ $-113.76 |
GBX-739.00K ≈ $-89.91 |
0.790x | +539.60% |
| 2001-12-31 | GBX-1.17 Million ≈ $-142.11 |
GBX210.00K ≈ $25.55 |
-0.180x | -288.74% |
| 2000-12-31 | GBX-3.99 Million ≈ $-485.35 |
GBX-380.00K ≈ $-46.24 |
0.095x | +76.88% |
| 1999-12-31 | GBX-3.17 Million ≈ $-386.31 |
GBX-171.00K ≈ $-20.81 |
0.054x | -94.55% |
| 1998-12-31 | GBX-2.76 Million ≈ $-335.57 |
GBX-2.72 Million ≈ $-331.43 |
0.988x | +138.27% |
| 1997-12-31 | GBX1.03 Million ≈ $125.32 |
GBX-2.66 Million ≈ $-323.40 |
-2.581x | -1497.58% |
| 1996-12-31 | GBX10.93 Million ≈ $1.33K |
GBX2.02 Million ≈ $245.53 |
0.185x | +1283.15% |
| 1995-12-31 | GBX12.21 Million ≈ $1.49K |
GBX163.00K ≈ $19.83 |
0.013x | -95.81% |
| 1994-12-31 | GBX10.48 Million ≈ $1.27K |
GBX3.34 Million ≈ $405.89 |
0.318x | +748.91% |
| 1993-12-31 | GBX8.26 Million ≈ $1.01K |
GBX310.00K ≈ $37.72 |
0.038x | -90.31% |
| 1992-12-31 | GBX7.03 Million ≈ $855.47 |
GBX2.72 Million ≈ $331.19 |
0.387x | +249.12% |
| 1991-12-31 | GBX9.33 Million ≈ $1.14K |
GBX-2.42 Million ≈ $-294.69 |
-0.260x | -- |
About N4 Pharma PLC
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequen… Read more